[go: up one dir, main page]

AR069801A1 - Derivados de aminotriazol - Google Patents

Derivados de aminotriazol

Info

Publication number
AR069801A1
AR069801A1 ARP080105522A ARP080105522A AR069801A1 AR 069801 A1 AR069801 A1 AR 069801A1 AR P080105522 A ARP080105522 A AR P080105522A AR P080105522 A ARP080105522 A AR P080105522A AR 069801 A1 AR069801 A1 AR 069801A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
alkoxy
substituents
compound
Prior art date
Application number
ARP080105522A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR069801A1 publication Critical patent/AR069801A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

También se reivindica composicion farmacéutica, medicamento y su uso como compuestos farmacéuticamente activos para enfermedades inflamatorias. Reivindicacion 1: Un compuesto de la formula (1), en la cual A representa un grupo fenilo- o un heterociclilo, en el cual los dos sustituyentes están en una disposicion 1,3; o A representa propan-1,3-diilo; E representa *- alquilo C1-4-O-, -CH=CH- o como el resto de formula (2) donde los asteriscos indican el enlace que está ligado a R1; Q representa O o S; R3 representa hidrogeno, alquilo C1-4, ciclopropilo, alcoxi C1-4-alquilo C1-4, bencilo o -CH2CH2C(O)OtBu; R1 representa un grupo piridilo o un grupo arilo, donde dicho grupo está no sustituido, mono-, di- o tri-sustituido, donde los sustituyentes están seleccionados independientemente del grupo que consiste en halogeno, alquilo C1-4, alcoxi C1-4, fluoralquilo C1-4, fluoralcoxi C1-4, di-[alquilo C1-3]-amino y alcoxi C1-4-alquilo C1-2; y R2 representa -CO-alquilo C1-3, -CF2-alquilo C1-3, o -SO2-alquilo C1-3; o una sal de dicho compuesto.
ARP080105522A 2007-12-18 2008-12-18 Derivados de aminotriazol AR069801A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23

Publications (1)

Publication Number Publication Date
AR069801A1 true AR069801A1 (es) 2010-02-17

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105522A AR069801A1 (es) 2007-12-18 2008-12-18 Derivados de aminotriazol

Country Status (25)

Country Link
US (1) US8536209B2 (es)
EP (1) EP2225231B1 (es)
JP (1) JP4656674B2 (es)
KR (1) KR101213007B1 (es)
CN (1) CN101903378B (es)
AR (1) AR069801A1 (es)
AT (1) ATE520689T1 (es)
AU (1) AU2008337097B2 (es)
BR (1) BRPI0821115A8 (es)
CA (1) CA2706839C (es)
CY (1) CY1112465T1 (es)
DK (1) DK2225231T3 (es)
HR (1) HRP20110825T1 (es)
IL (1) IL206399A (es)
MA (1) MA31949B1 (es)
MX (1) MX2010006241A (es)
MY (1) MY153985A (es)
NZ (1) NZ586735A (es)
PL (1) PL2225231T3 (es)
PT (1) PT2225231E (es)
RU (1) RU2492167C2 (es)
SI (1) SI2225231T1 (es)
TW (1) TWI434685B (es)
WO (1) WO2009077990A1 (es)
ZA (1) ZA201005080B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
ES2431298T3 (es) * 2009-05-18 2013-11-25 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2
MY161243A (en) * 2009-06-09 2017-04-14 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
CN102803237B (zh) * 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
PT2649068E (pt) * 2010-12-07 2014-12-23 Actelion Pharmaceuticals Ltd Derivados de éter oxazolil-metílico como agonistas do receptor de alx
JP5923108B2 (ja) * 2010-12-07 2016-05-24 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd Alx受容体アゴニストとしてのヒドロキシル化アミノトリアゾール誘導体
EP2707373A1 (de) 2011-05-10 2014-03-19 Bayer Intellectual Property GmbH Bicyclische (thio)carbonylamidine
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
ES2596521T3 (es) 2012-05-16 2017-01-10 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano sustituidos con puente 1-(p-tolil)ciclopropilo como agonistas de receptor de ALX
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
EP2925746A1 (en) * 2012-12-03 2015-10-07 F. Hoffmann-La Roche AG Substituted triazole and imidazole compounds
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
RU2016105310A (ru) 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SI3075726T1 (en) 2013-11-28 2018-05-31 Kyorin Pharmaceutical Co., Ltd. DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
HUE040555T2 (hu) 2013-12-04 2019-03-28 Idorsia Pharmaceuticals Ltd Benzimidazol prolin származékok alkalmazása
AR104751A1 (es) 2015-05-27 2017-08-09 Kyorin Seiyaku Kk Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR20180081528A (ko) * 2015-11-24 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅
HUE058044T2 (hu) 2018-03-05 2022-06-28 Bristol Myers Squibb Co Fenilpirrolidinon-formil peptid 2 receptor agonisták
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
JP7743010B2 (ja) * 2021-03-12 2025-09-24 国立大学法人 長崎大学 ハロカルボニル化合物の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
WO2003035006A2 (en) 2001-10-26 2003-05-01 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Amyloid ss is a ligand for fpr class receptors
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
ES2341473T3 (es) * 2004-12-13 2010-06-21 Leo Pharma A/S Compuestos de aminobenzofenona sustituida con triazol.
JP2009514858A (ja) * 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2008289485B2 (en) 2007-08-21 2014-08-14 Senomyx, Inc. Human T2R bitterness receptors and uses thereof
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
ES2431298T3 (es) 2009-05-18 2013-11-25 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2
MY161243A (en) 2009-06-09 2017-04-14 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
CN102803237B (zh) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物

Also Published As

Publication number Publication date
DK2225231T3 (da) 2011-10-17
MY153985A (en) 2015-04-30
TW200932216A (en) 2009-08-01
MX2010006241A (es) 2010-06-30
KR20100092516A (ko) 2010-08-20
EP2225231B1 (en) 2011-08-17
IL206399A (en) 2016-03-31
TWI434685B (zh) 2014-04-21
RU2010129272A (ru) 2012-01-27
ZA201005080B (en) 2011-12-28
BRPI0821115A8 (pt) 2017-12-26
US20100331378A1 (en) 2010-12-30
PT2225231E (pt) 2011-10-19
RU2492167C2 (ru) 2013-09-10
CN101903378A (zh) 2010-12-01
JP4656674B2 (ja) 2011-03-23
WO2009077990A1 (en) 2009-06-25
CA2706839A1 (en) 2009-06-25
AU2008337097B2 (en) 2014-03-20
EP2225231A1 (en) 2010-09-08
PL2225231T3 (pl) 2012-01-31
US8536209B2 (en) 2013-09-17
SI2225231T1 (sl) 2011-12-30
CA2706839C (en) 2015-10-20
BRPI0821115A2 (pt) 2015-06-16
KR101213007B1 (ko) 2012-12-20
HK1144158A1 (en) 2011-01-28
ATE520689T1 (de) 2011-09-15
IL206399A0 (en) 2010-12-30
HRP20110825T1 (hr) 2011-12-31
AU2008337097A1 (en) 2009-06-25
JP2011506594A (ja) 2011-03-03
NZ586735A (en) 2012-06-29
CN101903378B (zh) 2014-03-12
CY1112465T1 (el) 2015-12-09
MA31949B1 (fr) 2010-12-01

Similar Documents

Publication Publication Date Title
AR069801A1 (es) Derivados de aminotriazol
AR069650A1 (es) Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
SA520420033B1 (ar) مركبات صيدلية
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR075587A1 (es) Derivados de bifenilo para el tratamiento de hepatitis c
MA38138A1 (fr) Dérivés inédits de quinolone
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
AR078508A1 (es) Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
AR075396A1 (es) Derivados de quinazolinas y composiciones farmaceuticas
BRPI0818006B8 (pt) compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
PA8635201A1 (es) Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
RU2013127655A (ru) Фармацевтическая комбинация паклитаксела и ингибитора cdk

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee